Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)

Maxcyte has reported Non-Current Deffered Revenue over the past 2 years, most recently at $344600.0 for Q3 2022.

  • Quarterly Non-Current Deffered Revenue changed N/A to $344600.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $344600.0 through Sep 2022, changed N/A year-over-year, with the annual reading at $450200.0 for FY2021, N/A changed from the prior year.
  • Non-Current Deffered Revenue was $344600.0 for Q3 2022 at Maxcyte, down from $450200.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $450200.0 in Q4 2021 and troughed at $344600.0 in Q3 2022.